Patents involving antibody medicines (antibody patents) are largely grouped into patents specified by antibody amino acid sequences (antibody sequence-based patents) and those not (non-sequence-based patents). Non-sequence-based patents have a broad scope and are thus very useful for protecting antibody medicines. Here, I investigate a recent trend in antibody patents characterized by an antibody-binding site in an antigen.
Case Study: Recently Granted Epitope-Based Antibody Patents in the United States, Europe and Japan
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Federal Circuit Invalidates Mobile Device Targeted Ad Claims on Section 101 Cross-Appeal
- Patent Filings Roundup: Microsoft Battles Daedalus Blue; Intel Gears Up for First-to-File Fight; Electric Blanket Boogaloo
- Eleven Million Patents: Milestones in the History of Invention
- Assessing the Damage from Our COVID Technology Giveaway
- PPAC Meeting: Filings Down Less Than Expected Overall, Office Calls on Congress to Release Previously Collected Fees
Recent Posts
- Federal Circuit Invalidates Mobile Device Targeted Ad Claims on Section 101 Cross-Appeal
- Patent Filings Roundup: Microsoft Battles Daedalus Blue; Intel Gears Up for First-to-File Fight; Electric Blanket Boogaloo
- Eleven Million Patents: Milestones in the History of Invention
- Assessing the Damage from Our COVID Technology Giveaway
- PPAC Meeting: Filings Down Less Than Expected Overall, Office Calls on Congress to Release Previously Collected Fees